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There is increasing scrutiny of pharmaceuticals on their value proposition as well as 
a growing demand for evidence on real world effectiveness once they are commer-
cially available. There are many challenges in producing valid and reliable estimates 
of real world effectiveness. A major challenge is assessing a product’s effectiveness 
relative to why patients may respond differently to a treatment (i.e., identifying 
groups of patients exhibiting “Heterogeneity of Treatment Effect” (HTE) using sub-
group identification methods). Assessing HTE is critical to understanding differ-
ences that may exist between the efficacy observed in randomized clinical trials 
and a product’s real world effectiveness. Understanding causes for HTE is required 
for correct attribution of any observed difference between efficacy and effectiveness 
to the product versus other sources (e.g., patient behavior); Not recognizing and 
accounting for HTE will confound assessment of a product’s performance, which 
ultimately affects its acceptance and use by payers, physicians, and patients. Failure 
to define and incorporate subgroups is a frequent criticism of systematic evidence 
reviews and comparative effectiveness research reports. However, the analytical 
methods for finding factors that define subgroups that explain HTE are challenging 
due to many known statistical issues (e.g., limited statistical power, multiplicity 
adjustments) Real world data exacerbates the analytical challenges due in part to 
biases (e.g., selection bias) and issues (e.g., data quality) inherent in the data. We 
will describe the data and bias challenges that create these analytical complexi-
ties for detecting the cause and magnitude of HTE when using real world data. We 
will present results from a simulation experiment that compared and validated 
several subgroup methods developed to address these data and analytical issues. 
We simulated 22 permutations of subgroups with known identification criteria and 
treatment effects to determine the performance of the methods.
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Objectives: The Electronic Patient Reported Outcome (ePRO) data collection 
mode selected for trials is often based on efforts to minimize timelines, budg-
ets, and patient burden. However, are sponsors inadvertently introducing bias 
into trial results in this selection process? This conceptual paper reviews com-
mon ePRO modes and explores patient groups that may be excluded. MethOds: 
Common modes for ePRO data collection are reviewed. An assessment of potential 
patient groups that may be excluded is performed based on ePRO mode. Results: 
Common ePRO modes include telephone, web, and handheld device. As sponsors 
look to reduce costs, improve data quality, and reduce patient burden, industry has 
continued its shift towards patients using their own telephone, computer, tablet, 
or smartphone and away from sponsors provisioning these devices to patients. 
Choice of patient-provisioned device: Patients from certain geographic areas may 
be excluded where internet connections and cellular/mobile telephone reception 
is limited. Requiring patients to use their personal web/mobile device may exclude 
patient groups with certain economic, cultural, or demographic characteristics 
who live in rural or underdeveloped areas. Choice of sponsor-provisioned device: 
Logistics issues, i.e. shipment of devices including customs considerations, reli-
ability of data transmission, storage and replacement of devices and cords, train-
ing, etc. cOnclusiOns: The objective of clinical trials is to establish treatment 
effectiveness, generalizable to the overall patient population. ePRO mode selection 
may impact inclusion of individuals from certain economic, cultural, demographic, 
and geographic areas. Exclusion of these groups could impact results; therefore, it is 
important to understand the potential bias that can be introduced when selecting 
an ePRO mode. Proper planning should include assessment of patient population 
and inclusion of regions that would render generalizability. ePRO mode selection 
should be based on which method works best for the required regions to optimize 
inclusion, as well as the patient population’s characteristics to minimize burden.
PRM243
clInIcal outcoME assEssMEnt (coa) InstRuMEnt scoRIng: thE 
ValIDIty anD PREcIsIon of unwEIghtED suMMaRy scoREs VERsus IRt 
wEIghtED scoREs, anD thE aDDED ValuE of IRt stanDaRD ERRoRs
Coon C.D.1, Lenderking W.R.2
1Adelphi Values, Boston, MA, USA, 2Evidera, Lexington, MA, USA
COA development experts in recent years have given thought to the psychomet-
ric evaluation of instruments and their ability to detect meaningful differences 
between patient groups. The scoring of the instruments, however, has received less 
attention, with various approaches sometimes suggested without a clear prefer-
ence or justification. The score is ultimately used for evaluating patient outcomes 
and treatment efficacy and is what requires validation, so this seems like a signifi-
cant omission. We examine the traditionally accepted unweighted summary score 
approach and compare it to the more complex IRT weighted scoring to evaluate if 
the gain in precision justifies the increased scoring complexity. Precision may differ 
depending on whether the score is close to the mean of the population or closer to 
the extreme ends of the distribution. Simulated data are used for this comparison to 
evaluate if the precision of the scores differs depending on the location of the score 
and if the instrument is used for group comparisons versus individual diagnosis. 
Additionally, we recognize that the reliability of a scale is likely to be variable across 
the range of its scores. With that in mind, we consider an approach to comparing 
mean scores between groups that incorporates the standard error of each individual 
IRT score into the model. By using the IRT standard errors, we can adjust for the 
different levels of uncertainty associated with ranges of scores along the scale, 
ultimately providing us greater confidence in the group comparison results.
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making, reduced patient benefits and less efficient use of public resources. Within 
individual agencies, prioritisation is also a business function that must balance the 
need to plan for and manage the allocation of resources with the need to provide 
expeditious advice to decision makers and adapt quickly to changing circumstances. 
This research describes a transparent and responsive framework for selecting health 
technologies to assess, minimising the potential for important technologies to be 
missed and providing a useful resource for HTA agencies facing similar issues. 
Topics are identified through a mix of routine horizon scanning, a formally convened 
advisory group consisting of the major decision makers from within the publicly 
funded health system and informal business intelligence gathering. Screening is 
carried out to eliminate technologies that are clearly unsuitable and provision-
ally grade all remaining candidates according to three principal criteria; 1) clinical 
impact (patient population, potential incremental effect and availability of alterna-
tives); 2) economic impact (incremental costs and potential disruptive effect on how 
services are currently organised) and 3) policy impact (link to decision-making and 
factors that make it likely to feature on the national health care agenda). The screen-
ing process feeds into an in-depth expert group discussion, which also considers 
operational issues such as the extent of the advice required to inform the decision, 
data availability and costs associated with the assessment. We also describe a soft-
ware visualisation tool developed to facilitate the prioritisation process, as well as 
measures for quality assurance and ongoing performance evaluation.
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Goal Attainment Scales (GAS) capture outcomes relevant to individual patients and 
provide “real-world” outcome measurement. This abstract will describe the back-
ground to their use, their operationalization, strengths and limitations. Traditional 
outcome measures assess a standardised set of questions regardless of their relevance 
to each patient. GAS overcomes these weaknesses because it is an individualised 
assessment based on achievement of goals which are personal to each patient. 
Despite its widely cited use in academic literature and good psychometric proper-
ties it is rarely used in drug intervention studies. Operationalisation of GAS varies 
but follows these basic steps: 1) The patient’s specific problem areas are assessed and 
goals for each defined; 2) A GAS for each goal is created and an “expected outcome” for 
each agreed; 3) Goal attainment levels are defined for each point on, typically, a 5-point 
scale (expected outcomes are usually scored 0; baseline is often -2, but may be -1 or 
0 depending on potential for deterioration). Each level must be carefully described 
in a way that is relevant, observable, measurable and consistent with study design. 
Published standardised goals are available; and 4) A standardized statistical formula 
provides overall goal attainment. Benefits include: ease of use; relevant goals; no 
redundant items; assessment of multiple domains; provides quantifiable and appli-
cable outcomes across different conditions and severities; potentially more sensitive 
measure than traditional scales. Limitations include: potential bias; appropriate goal 
selection and outcome prediction; observable changes may differ from pre-defined 
outcomes; time consuming; may require independent GAS assessors for blinded tri-
als; may require “control” goals not affected by treatment; statistical issues around 
single overall score. In capturing those outcomes relevant to each individual patient, 
GAS has potential use in supporting product labeling claims and value assessment 
of a medicine by HTA and payers.
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Health economic models have become the primary vehicle for undertaking eco-
nomic evaluation and are used in various health care jurisdictions across the world 
to inform decisions about the use of new and existing health technologies. Models 
are required because a single source of evidence, such as a randomised controlled 
trial, is rarely sufficient to provide all relevant information about the expected costs 
and health consequences of all competing decision alternatives. Whilst models are 
used to synthesise all relevant evidence, they also contain assumptions, abstractions 
and simplifications. By their very nature, all models are therefore “wrong.” Whilst 
the presence of imperfect evidence provides the impetus for developing models, it is 
also the reason why we can never fully validate them. As such, the interpretation of 
estimates of the cost-effectiveness of health technologies requires careful judgements 
about the degree of confidence that can be placed in the models from which they 
are drawn. The presence of a single error or inappropriate judgement within a model 
may lead to inappropriate decisions, an inefficient allocation of health care resources 
and ultimately suboptimal outcomes for patients. This study sets out a taxonomy 
of threats to the credibility of health economic models. The taxonomy segregates 
threats to model credibility into three broad categories (1) unequivocal errors, (2) 
violations and (3) matters of judgement, and maps these across the main elements of 
the model development process. These three categories of threats to model credibility 
are defined according to the existence of criteria for judging correctness, the degree 
of force with which such criteria can be applied, and the means by which potential 
threats can be handled. A range of suggested processes and techniques for avoid-
ing and identifying these threats is put forward with the intention of prospectively 
increasing the credibility of any given model.
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